Stocks and Investing Stocks and Investing
Fri, October 23, 2020
Thu, October 22, 2020

Evan Seigerman Maintained (BIIB) at Buy with Decreased Target to $350 on, Oct 22nd, 2020


Published on 2024-10-27 14:27:59 - WOPRAI, Evan Seigerman
  Print publication without navigation


Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $359 to $350 on, Oct 22nd, 2020.

Evan has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 3 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $265 on, Tuesday, October 20th, 2020
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, September 18th, 2020
  • Carter Gould of "Barclays" Downgraded from Buy to Hold and Decreased Target to $280 on, Monday, June 22nd, 2020


These are the ratings of the 2 analyists that currently disagree with Evan


  • Geoff Meacham of "B of A Securities" Maintained at Sell with Decreased Target to $235 on, Thursday, October 15th, 2020
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $342 on, Wednesday, August 19th, 2020
Contributing Sources